Effect of Disease State on the Pharmacokinetics of Bedaquiline in Renal-Impaired and Diabetic Rats

Effect of Disease State on the Pharmacokinetics of Bedaquiline in Renal-Impaired and Diabetic Rats

Bibliographic Details
Main Authors:	Abhishek Gour, Ashish Dogra, Sumit Sharma, Priya Wazir, Utpal Nandi
Format:	Article
Language:	English
Published:	American Chemical Society 2021-03-01
Series:	ACS Omega
Online Access:	https://doi.org/10.1021/acsomega.0c06165

Similar Items

Effect of Concomitant Hydroxyurea Therapy with Rutin and Gallic Acid: Integration of Pharmacokinetic and Pharmacodynamic Approaches
by: Abhishek Gour, et al.
Published: (2021-05-01)

Description of Druglike Properties of Safranal and Its Chemistry behind Low Oral Exposure
by: Ashish Dogra, et al.
Published: (2020-04-01)

Analyzing the Effect of Resveratrol on Pharmacokinetics of Antituberculosis Drug Bedaquiline in Rats by a Novel UPLC-MS/MS Approach
by: Yun Ye, et al.
Published: (2024-11-01)

In vitro evaluation of poloxamer in situ forming gels for bedaquiline fumarate salt and pharmacokinetics following intramuscular injection in rats
by: Sandy Van Hemelryck, et al.
Published: (2019-12-01)

Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients
by: Ge Shao, et al.
Published: (2023-03-01)

Effect of Renal Impairment on the Pharmacokinetics of Memantine
by: Takashi Moritoyo, et al.
Published: (2012-01-01)

Bioanalysis of bedaquiline in human plasma by liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic study
by: Viritha Bezawada, et al.
Published: (2024-01-01)

In Vitro Evaluation of Poly(lactide-co-glycolide) In Situ Forming Gels for Bedaquiline Fumarate Salt and Pharmacokinetics Following Subcutaneous Injection in Rats
by: Sandy Van Hemelryck, et al.
Published: (2021-08-01)

Pharmacokinetics of bempedoic acid in patients with renal impairment
by: Benny M. Amore, et al.
Published: (2022-03-01)

Pharmacokinetic profile of defibrotide in patients with renal impairment
by: Tocchetti P, et al.
Published: (2016-08-01)

Coadministration of bedaquiline and pyrifazimine reduce exposure to toxic metabolite N-desmethyl bedaquiline
by: Yangming Ding, et al.
Published: (2023-10-01)

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
by: Hu MH, et al.
Published: (2016-12-01)

Cardiac toxicity of fluoroquinolones and bedaquiline
by: G. N. Mozhokinа, et al.
Published: (2019-05-01)

Bedaquiline and clofazimine: successes and challenges
by: Norbert Ndjeka, et al.
Published: (2020-08-01)

A modeling‐based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study
by: Lina Keutzer, et al.
Published: (2022-05-01)

Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
by: Borin MT, et al.
Published: (2019-10-01)

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
by: Ishani Landry, et al.
Published: (2021-04-01)

Bedaquiline in the treatment of extensively drugresistant tuberculosis
by: T. I. Morozova, et al.
Published: (2022-04-01)

Acquired resistance of Mycobacterium tuberculosis to bedaquiline.
by: Koen Andries, et al.
Published: (2014-01-01)

Bedaquiline overdose: A case report
by: Oleksandr Telnov, et al.
Published: (2019-07-01)

Correction to “Improved Synthesis and Isolation of Bedaquiline”
by: Hlengekile Lubanyana, et al.
Published: (2020-09-01)

Public investments in the clinical development of bedaquiline
by: Dzintars Gotham, et al.
Published: (2020-01-01)

Bedaquiline: Current status and future perspectives
by: Saeed Khoshnood, et al.
Published: (2021-06-01)

Public investments in the clinical development of bedaquiline.
by: Dzintars Gotham, et al.
Published: (2020-01-01)

Bedaquiline resistance and genetic resistance associated variants: South African National Bedaquiline Surveillance program 2014–2019
by: S.V. Omar, et al.
Published: (2020-12-01)

A Comprehensive Physiologically Based Pharmacokinetic Model for Predicting Vildagliptin Pharmacokinetics: Insights into Dosing in Renal Impairment
by: Mahnoor Pasha, et al.
Published: (2024-07-01)

Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes
by: Yoshiko Tomita, et al.
Published: (2022-04-01)

Temporary Persistence of Bedaquiline-resistant Mycobacterium tuberculosis Isolates under Bedaquiline Pressure as a Model to Explore Resistance Mechanisms
Published: (2024-08-01)

Minimal effective dose of bedaquiline administered orally and activity of a long acting formulation of bedaquiline in the murine model of leprosy.
by: Aurélie Chauffour, et al.
Published: (2023-11-01)

PHARMACOKINETICS AND PHARMACODYNAMICS OF ANTIMICROBIAL AGENTS IN PATIENTS WITH IMPAIRED RENAL FUNCTION: AMINOGLYCOSIDES
by: M. Kolesnyk, et al.
Published: (2017-12-01)

Effects of Diabetes Mellitus Induced by Alloxan on the Pharmacokinetics of Metformin in Rats: Restoration of Pharmacokinetic Parameters to the Control State by Insulin Treatment
by: Myung G. Lee, et al.
Published: (2008-03-01)

Safety of prolonged treatment with bedaquiline in programmatic conditions
by: Dzmitriy Zhurkin, et al.
Published: (2022-05-01)

EMERGENCE OF BEDAQUILINE RESISTANCE AFTER COMPLETION OF BEDAQUILINE-BASED DRUGRESISTANT TB TREATMENT: A CASE STUDY FROM SOUTH AFRICA
by: M. de Vos, et al.
Published: (2018-12-01)

Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis
by: Liang Fu, et al.
Published: (2021-10-01)

Population Pharmacokinetic/Pharmacodynamic Modelling of Daptomycin for Schedule Optimization in Patients with Renal Impairment
by: Teresa García-Martínez, et al.
Published: (2022-10-01)

Simulation-Based Analysis of the Impact of Renal Impairment on the Pharmacokinetics of Highly Metabolized Compounds
by: Kristin E. Follman, et al.
Published: (2019-03-01)

Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics
by: Kit Wun Kathy Cheung, et al.
Published: (2024-04-01)

The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end-stage renal disease: A case report
by: Seyeon Park, et al.
Published: (2018-11-01)

The use of bedaquiline in children in the treatment of multidrug-resistant tuberculosis
by: Valentina Romanenko, et al.
Published: (2024-12-01)

IMPACT OF BEDAQUILINE ON THE EFFICIENCY OF COMPREHENSIVE THERAPY OF RESPIRATORY TUBERCULOSIS
by: M. N. Kondakova, et al.
Published: (2018-07-01)